Copernicus Podmiot Leczniczy Sp. z o.o.

The oncology unit at Copernicus Podmiot Leczniczy conducts extensive research on solid tumors, testing innovative treatments to improve survival and quality of life.

• Advanced colorectal cancer with KRAS G12C mutation
• Metastatic renal cell carcinoma
• Hepatocellular carcinoma
• Non‑small cell lung cancer
• ER+/HER2‑ breast cancer (locally advanced or metastatic)

With 72 active trials and 36 investigators, the site is a regional hub for cancer research in Gdańsk.

Research in blood‑related malignancies targets novel targeted agents and immune‑based strategies, aiming to achieve deeper remissions.

• Chronic lymphocytic leukemia
• Mantle cell lymphoma
• Follicular lymphoma
• B‑cell malignancies
• High‑risk chronic lymphocytic leukaemia

The department collaborates closely with hematology specialists to integrate translational insights.

Cardiovascular studies evaluate therapies that lower major adverse cardiac events and support heart‑failure management across diverse patient groups.

• Adults at high risk of cardiovascular events without prior MI or stroke
• Chronic heart failure with renal impairment
• Hypertension
• ST‑elevation and non‑ST‑elevation myocardial infarction
• Heart failure with preserved ejection fraction

Several large‑scale outcome studies are ongoing, reflecting the site’s strong cardiology expertise.

Investigations in gastrointestinal oncology and inflammatory bowel disease assess new biologics and combination regimens to induce remission and extend survival.

• Advanced gastric cancer
• Gastroesophageal junction adenocarcinoma expressing CLDN18.2
• Ulcerative colitis (moderate to severe)
• Colorectal cancer with BRAF V600E mutation
• Short bowel syndrome

A multidisciplinary team integrates gastroenterology and oncology to streamline patient enrollment.

Trials focus on autoimmune conditions, exploring monoclonal antibodies and small molecules to modulate immune pathways and achieve durable control.

• Atopic dermatitis
• Chronic spontaneous urticaria
• Immune thrombocytopenia (ITP)
• Primary infection prophylaxis in CLL with secondary immunodeficiency
• Multiple sclerosis

Pediatric cohorts are included in studies of dupilumab and nemolizumab to address early‑onset disease.

Neurological research aims to slow disease progression and improve motor function through disease‑modifying agents and innovative delivery methods.

• Early Parkinson’s disease
• Multiple system atrophy
• Primary progressive multiple sclerosis
• Prodromal and early manifest Huntington’s disease
• Refractory focal onset epilepsy

Advanced imaging and biomarker analyses support the trials, enhancing mechanistic understanding.

Dermatology studies evaluate targeted therapies for chronic inflammatory skin disorders, seeking long‑term disease control and improved quality of life.

• Atopic dermatitis
• Chronic spontaneous urticaria
• Moderate to severe plaque psoriasis
• Distal subungual onychomycosis
• Upper limb spasticity after stroke or traumatic brain injury

Pediatric participants are included in trials of dupilumab and nemolizumab, expanding therapeutic options for children.

Metabolic investigations test agents that affect glucose regulation, lipid metabolism, and anemia management, aiming to reduce complications and enhance daily functioning.

• Transfusion‑dependent α‑ or β‑thalassemia
• Low‑risk myelodysplastic syndromes
• Hypertension
• High cardiovascular risk metabolic syndrome
• Short bowel syndrome

Trials frequently incorporate quality‑of‑life assessments alongside laboratory endpoints.

Infection‑focused trials examine new antifungal agents and antibacterial strategies to improve cure rates and limit resistance.

• Distal subungual onychomycosis
• Primary infection prophylaxis in CLL with secondary immunodeficiency
• Infections associated with short bowel syndrome
• Severe bacterial sepsis in immunocompromised patients
• Opportunistic fungal infections in hematologic malignancies

Safety monitoring and antimicrobial resistance profiling are core components of these studies.

Psychiatric research addresses depressive and anxiety symptoms in patients with chronic medical conditions, testing integrated therapeutic approaches that combine pharmacology and psychosocial support.

• Depressive‑anxiety states in heart failure with preserved ejection fraction
• Anxiety and mood disturbances in Parkinson’s disease
• Psychological impact of chronic lymphocytic leukemia treatment
• Depression in patients with advanced renal cell carcinoma
• Mood disorders associated with multiple sclerosis

Outcomes include validated mood scales, functional assessments, and patient‑reported quality of life.

A subset of studies explores emerging indications that span multiple organ systems, focusing on safety and feasibility of novel platforms across diverse patient populations.

• Pan tumor roll‑over study
• Zanzalintinib combination trials in advanced solid tumors
• Tominersen in Huntington’s disease
• Prasinezumab in early Parkinson’s disease
• Ziltivekimab in acute myocardial infarction

These trials illustrate the site’s capacity to support innovative, cross‑disciplinary research initiatives.